FDA Recalls Finder

FDA approves Erwinaze to treat a form of leukemia
18 November 2011, 7:46 am

The U.S. Food and Drug Administration today approved Erwinaze (asparaginase Erwinia chrysanthemi) to treat patients with acute lymphoblastic leukemia (ALL), who have developed an allergy (hypersensitivity) to E. coli derived asparaginase and pegapargase chemotherapy drugs used to treat ALL.

Source: Food and Drug Administration--Press Releases